Last reviewed · How we verify
NCT06656611: PAPMOBILE
Mobile Outreach Screening of High-Risk Human Papillomavirus Infection in Women with Limited Access to Health Services in Seine-Saint-Denis (greater Paris Area, France)
NA trial testing HPV self sampling in Women's Health: Cervical Neoplasm in 700 participants. Not yet recruiting.
30 July 2026
Quick facts
| Lead sponsor | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 700 |
| Start date | 1 December 2024 |
| Primary completion | 30 July 2026 |
| Estimated completion | 30 July 2026 |
| Sites | 1 location across France |
Drugs / interventions tested
- HPV self sampling
Conditions studied
- Women's Health: Cervical Neoplasm — all drugs for Women's Health: Cervical Neoplasm →
Sponsor
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba — full company profile →
Who can join
Adults 30 to 65, female only, with Women's Health: Cervical Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a prospective cervical cancer screening intervention in the nonclinical setting of a mobile testing unit in a vehicle, using point-of-care HPV PCR tests with self-collected vaginal swabs. It is designed for women with limited access to healthcare and prevention in underprivileged municipalities in the greater Paris area (Seine-Saint-Denis department, detailed in Annexe 3). HPV positive participants will receive counseiling and guidance to help them find a healthcare professional to take care of their needs
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06656611
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba trials
Trials by the same sponsor.
- NCT07402044 — CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074) · not yet recruiting
- NCT06657885 — CAbotégravir LENacapavir DUal Long Acting · Phase 2 · withdrawn
- NCT06649396 — Determination of New Detection and Quantification Thresholds for Serological and Molecular Tests for Hepatitis Delta Vir · NA · not yet recruiting
- NCT06289361 — Cohort IMEA 070 -Lenacapavir Compassional · active not recruiting
- NCT05761509 — "Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk" · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06656611 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
- Last refreshed: 24 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06656611.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing